Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose parallel, randomized, placebo-controlled, multicenter study of the safety and efficacy of multiple regimens of the combination of zonisamide CR plus bupropion SR in the treatment of subjects with uncomplicated obesity

X
Trial Profile

A dose parallel, randomized, placebo-controlled, multicenter study of the safety and efficacy of multiple regimens of the combination of zonisamide CR plus bupropion SR in the treatment of subjects with uncomplicated obesity

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion/zonisamide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Orexigen Therapeutics [CEASED]
  • Most Recent Events

    • 06 Oct 2008 Long-term (over 48 weeks) data presented at the Obesity Society Annual Scientific Meeting.
    • 09 May 2008 48-week results were reported in January 2008.
    • 08 Jan 2008 Results data for 24-week extension study (total 48-week study duration) available.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top